SCHEMBL19951244

SCHEMBL19951244

CNC(=O)c1cccc(Cn2nc(C)c(NC(=O)c3ccc(COc4cccc(OC)c4)cc3)c2C)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.57
ALDH1A1 P00352 5/20 0.57
LMNA P02545 5/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
HTT P42858 3/20 0.57
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2C9 P11712 2/20 0.56
CYP2C19 P33261 2/20 0.56
GAA P10253 2/20 0.51
TSHR P16473 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2D6 P10635 1/20 0.51
TAAR1 Q96RJ0 1/20 0.51
PLA2G1B P04054 1/20 0.49
ATG4B Q9Y4P1 1/20 0.49
P2RY14 Q15391 1/20 0.48
MRGPRX4 Q96LA9 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19951258 0.94 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951304 0.92 SMN1; SMN2 (0.57) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951326 0.92 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951228 0.91 SMN1; SMN2 (0.67) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951211 0.91 SMN1; SMN2 (0.62) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951197 0.90 SMN1; SMN2 (0.62) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951245 0.89 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951348 0.89 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951217 0.89 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A
SCHEMBL19951281 0.89 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357477-B2 Anticancer compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2019-07-23 US disclosed
US-10357477-B2 Anticancer compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2019-07-23 US disclosed
US-20180071258-A1 ANTICANCER COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-03-15 US disclosed
US-20180071258-A1 ANTICANCER COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071258-A1 ANTICANCER COMPOUNDS RB1, MCL1, TP53 SMN1; SMN2 2882/4885ALDH1A1 757/4885LMNA 126/4885
US-10357477-B2 Anticancer compounds RB1, MCL1, TP53 SMN1; SMN2 2882/4885ALDH1A1 757/4885LMNA 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.